检查点抑制剂肺炎诊断与管理中国专家共识(2025)
本共识由北京协和医院呼吸与危重症医学科发起,联合多个专业委员会共同制定,针对免疫检查点抑制剂相关肺炎(CIP)的危险因素、临床特征、诊断评价、诊断标准、鉴别诊断、治疗策略及康复方案形成18条专家推荐,旨在规范CIP诊疗并改善患者预后。
要点
- CIP是少见的免疫相关不良反应,但可导致呼吸衰竭或死亡。
- 早期识别、诊断和及时合理治疗可改善大多数患者预后。
- 部分CIP患者经治疗后可考虑后续免疫再挑战。
核心结论
- 早期识别、诊断并及时合理治疗CIP可使大多数患者预后良好,部分患者可能适合后续免疫再挑战。
研究设计与样本
- 由北京协和医院呼吸与危重症医学科发起,中国抗癌协会肿瘤呼吸病专业委员会、中华医学会呼吸病学分会肺癌学组和北京肿瘤防治研究会共同组织专家讨论制定本共识。
主要发现
- CIP是少见的免疫相关不良反应,一旦发生会严重影响后续抗肿瘤免疫治疗,甚至导致呼吸衰竭或死亡。
关键数值与推荐
- 共识从CIP的危险因素、临床特征、诊断评价措施、诊断标准、鉴别诊断、治疗策略及康复方案等方面形成18条专家推荐意见。
临床怎么用
- 临床医师可参考本共识对CIP进行规范诊疗,以改善患者预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Checkpoint inhibitor pneumonitis (CIP) is a rare type of immune-related adverse reaction, that can seriously affect the subsequent anti-tumor immunotherapy and even lead to respiratory failure or death. However, if identified and diagnosed early, and treated promptly and appropriately, most patients have a good prognosis, and some may be eligible for subsequent immune rechallenge. In order to standardize diagnosis and treatment of patients with CIP and improve their prognosis, the Department of Pulmonary and Critical Care Medicine of Peking Union Medical College Hospital initiated and developed the consensus, which was discussed and reached a consensus by experts from the Oncology Respiratory Disease Committee of China Anti-Cancer Association, Lung Cancer Group of Thoracic Society of Chinese Medical Association and Beijing Cancer Prevention and Treatment Research Association. The consensus formed 18 expert recommendations on the risk factors, clinical characteristics, diagnostic evaluation measures, diagnostic criteria, differential diagnosis, treatment strategies and rehabilitation plans of CIP for clinicians' reference. 抗肿瘤免疫治疗中并发的免疫检查点抑制剂相关肺炎(CIP)是少见的免疫相关不良反应类型,一旦发生,会严重影响后续的抗肿瘤免疫治疗,甚至导致呼吸衰竭或死亡。但若能及早被识别、诊断,并给予及时、合理的治疗,大多数患者预后良好,部分患者有可能后续接受免疫再挑战。为规范CIP的诊疗、改善其预后,由北京协和医院呼吸与危重症医学科发起,中国抗癌协会肿瘤呼吸病专业委员会、中华医学会呼吸病学分会肺癌学组和北京肿瘤防治研究会共同组织相关专家讨论后制订本共识。共识从CIP的危险因素、临床特征、诊断评价措施、诊断标准、鉴别诊断、治疗策略以及康复方案等方面,形成18条专家推荐意见,供临床医师参考。.
引用
- [Chinese experts consensus on the diagnosis and management of checkpoint inhibitor pneumonitis(2025)]. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 40159051. doi:10.3760/cma.j.cn112147-20241121-00694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。